Related Experiment Video
Updated: Jul 13, 2025

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
Exploring host-virus interaction to improve immunotherapy against Ebola virus
Dacquin M Kasumba1, John Misasi2, Sabue Mulangu3
1Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo; Axis of Molecular Immunology and Pathogenesis, Molecular Biology Unit, Department of Basic Sciences, Faculty of Medicine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo.
Abstract:
Recent immunological advances have led to the development of FDA-approved immunotherapies against Ebola virus (EBOV). However, patients with high viral loads have not seen as large a benefit as mild cases. Here we discuss areas of investigation that may lead to adjunctive immune therapy for patients with severe EBOV disease.
More Related Videos
Related Concept Videos
Cross-reactivity
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

